Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2023 1
2024 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. Among authors: oyervides juarez vm. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Protocol for Desensitization to Atezolizumab and Bevacizumab After Severe Anaphylaxis in the Treatment of Lung Adenocarcinoma.
Gonzalez-Diaz SN, Villarreal-Gonzalez RV, De Lira-Quezada CE, Rocha-Silva GK, Oyervides-Juarez VM, Vidal-Gutierrez O. Gonzalez-Diaz SN, et al. Among authors: oyervides juarez vm. J Investig Allergol Clin Immunol. 2021 Jun 22;31(3):265-267. doi: 10.18176/jiaci.0637. Epub 2020 Aug 26. J Investig Allergol Clin Immunol. 2021. PMID: 32856592 Free article. No abstract available.
Safety and oncological effectiveness after desensitization in patients with previous hypersensitivity reactions to chemotherapy.
Villarreal-González RV, Vidal-Gutiérrez O, Martínez-Moyano JA, Madrazo-Morales M, Sáenz-Cantú KS, Cadenas-García DE, Oyervides-Juárez VM, Noriega-Iriondo MF, Rodríguez-Niño P. Villarreal-González RV, et al. Among authors: oyervides juarez vm. J Oncol Pharm Pract. 2024 Aug 28:10781552241269766. doi: 10.1177/10781552241269766. Online ahead of print. J Oncol Pharm Pract. 2024. PMID: 39196645